
Balchem (BCPC) Stock Forecast & Price Target
Balchem (BCPC) Analyst Ratings
Bulls say
Balchem Corp is forecasted to achieve significant earnings growth, with expected GAAP earnings rising from $4.65 per diluted share in 2025 to $4.73 and further increasing to $5.17 per diluted share in 2026, highlighting strong operational performance. The company’s 2Q25 results indicated a revenue of $255.5 million, representing a year-over-year increase of 1% and sequential growth from the previous quarter, underscoring consistent demand, particularly in the Human Nutrition and Health segment. Additionally, Balchem's improving gross and net margins, along with the potential for a debt-free status by next year and opportunities for strategic mergers and acquisitions, contribute to a robust financial outlook.
Bears say
Balchem Corporation has experienced a decline in its applicable P/E multiple, decreasing from 39.6x to 37.9x, which reflects a slight uptick in their 12-month price target despite weakening market conditions among comparable companies. The company faces significant risks, including slower-than-anticipated growth in its core businesses, inflationary pressures, challenges in launching new nutrition products, and potential disruptions to operations stemming from regional conflicts affecting its European markets. Additionally, underperformance in sales within both the animal health and nutrition segment and the industrial products segment points to potential weaknesses in revenue generation, with 3Q25 sales falling short of estimates.
This aggregate rating is based on analysts' research of Balchem and is not a guaranteed prediction by Public.com or investment advice.
Balchem (BCPC) Analyst Forecast & Price Prediction
Start investing in Balchem (BCPC)
Order type
Buy in
Order amount
Est. shares
0 shares